Urinary Retention Therapeutics Market Report 2026

The urinary retention therapeutics market size has grown strongly in recent years. It will grow from $3.55 billion in 2025 to $3.79 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to rising prevalence of prostate-related disorders, increasing incidence of neurological conditions, improved diagnostic accuracy for bladder dysfunction, availability of multiple pharmacological options, expansion of hospital-based urology services.

The urinary retention therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.97 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to growing demand for targeted drug therapies, rising investments in urological research, increasing use of digital patient monitoring, expansion of outpatient therapeutic care, development of next-generation bladder control medications. Major trends in the forecast period include increasing use of combination drug therapies, rising adoption of personalized bladder treatment plans, growing focus on minimally invasive therapeutic options, expansion of novel pharmacological agents, enhanced monitoring of bladder function outcomes.

The increasing incidence of prostate cancer is expected to drive the growth of the urinary retention therapeutics market going forward. Prostate cancer is a malignant condition characterized by the uncontrolled growth of cells in the prostate gland. Its rising prevalence is linked to aging male populations, as more men reach higher-risk age groups. The urinary retention therapeutics market supports this growth by providing treatments and devices that manage urinary flow blockages often caused by prostate enlargement or tumor-related urethral obstruction. For example, in January 2023, the American Cancer Society, a US-based professional organization, reported that new prostate cancer cases in the US are projected to rise from 268,490 in 2022 to 288,300 in 2023, with deaths increasing slightly from 34,500 to 34,700. Therefore, the rising incidence of prostate cancer is fueling the growth of the urinary retention therapeutics market.

Key companies in the urinary retention therapeutics market are focusing on developing innovative solutions, such as sacral nerve stimulators, to improve bladder control, enhance patient quality of life, and reduce dependence on other interventions. A sacral nerve stimulator is a medical device that delivers mild electrical impulses to the sacral nerves near the lower spine to regulate bladder and bowel function. For instance, in November 2024, Medtronic plc, an Ireland-based medical technology company, launched the FDA-approved InterStim X Sacral Neuromodulation (SNM) system in India. This system is designed to treat overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention by delivering personalized sacral nerve stimulation that targets nerve signals controlling bladder and bowel functions. The therapy is administered in two stages, beginning with a trial using an external stimulator, followed by implantation of a pulse generator if successful, with a battery life exceeding 10 years without recharging.

In September 2023, Caldera Medical, a US-based women’s health medical device company, acquired Atlantic Therapeutics for an undisclosed amount. This acquisition allows Caldera Medical to strengthen its women’s health portfolio by incorporating the FDA-cleared Innova product family, which offers non-invasive treatments for stress urinary incontinence (SUI). Atlantic Therapeutics, based in Ireland, specializes in bladder control treatments, aligning with the urinary retention therapeutics segment.

Major companies operating in the urinary retention therapeutics market are Pfizer Inc. , Merck KGaA , Abbvie Inc. , Bayer AG , Sanofi SA , GlaxoSmithKline Plc. , Medtronic Plc , Boston Scientific Corp. , Sumitomo Pharma Inc. , Ipsen Pharma , Coloplast A/S , Dr. Reddy’s Laboratories , Cipla Limited , Amneal Pharmaceuticals Inc. , Ferring Pharmaceuticals , Astellas Pharma Inc. , Johnson & Johnson , Teva Pharmaceutical Industries Ltd. , Novartis International AG , Takeda Pharmaceutical Company Limited , Boehringer Ingelheim International GmbH , UroGen Pharma Ltd.

North America was the largest region in the urinary retention therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urinary retention therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary retention therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the urinary retention therapeutics market by increasing costs of imported active pharmaceutical ingredients, specialized formulations, medical-grade catheters, and drug delivery devices. North America and Europe are most affected due to reliance on cross-border pharmaceutical supply chains, while Asia-Pacific faces cost pressures on bulk drug exports. These tariffs are increasing therapy costs and impacting drug availability in certain regions. At the same time, they are encouraging domestic drug manufacturing, localized API production, and regional expansion of urology-focused pharmaceutical facilities.

The urinary retention therapeutics market research report is one of a series of new reports that provides urinary retention therapeutics market statistics, including urinary retention therapeutics industry global market size, regional shares, competitors with a urinary retention therapeutics market share, detailed urinary retention therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the urinary retention therapeutics industry. This urinary retention therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urinary retention therapeutics encompass a range of medical approaches aimed at treating the inability to fully empty the bladder. These treatments focus on relieving bladder pressure, restoring normal urinary flow, and preventing complications such as infections or kidney damage. The overall goal is to improve bladder function and enhance the patient’s comfort and quality of life.

The main urinary retention therapeutics include 5-alpha-reductase inhibitors and alpha-blocker drugs, anticholinergic or antispasmodic agents, antidepressants, skeletal muscle relaxants, topical estrogens, and others. 5-alpha-reductase inhibitors and alpha-blockers are primarily used to treat benign prostatic hyperplasia (BPH); the former reduces prostate size by blocking the hormone dihydrotestosterone (DHT), while the latter relaxes muscle fibers in the prostate and bladder neck to improve urine flow. These therapeutics are applied for conditions such as stress incontinence, urge incontinence, overflow incontinence, mixed incontinence, and others, and can be administered orally, intravesically, intravenously, or transdermally. They are distributed through channels including retail pharmacies, hospital pharmacies, and online pharmacies.

The urinary retention therapeutics market consists of revenues earned by entities by providing services such as drug development and formulation services, clinical trial management, regulatory consulting and medical device integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary retention therapeutics market also includes sales of catheters, prostate shrinking agents, urethral stents and sacral neuromodulation devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.